CTOs on the Move


 
97250 Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City.
  • Number of Employees: 10K-50K
  • Annual Revenue: > $1 Billion

Executives

Name Title Contact Details

Similar Companies

Specialty Therapeutic Care

Specialty Therapeutic Care is a Orlando, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Merz Pharmaceuticals

Merz Pharmaceuticals is a Greensboro, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alfagene Bioscience

Alfagene Bioscience is a Fords, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arena Pharmaceuticals

We are a biopharmaceutical company focused on developing novel, small molecule drugs with optimized receptor pharmacology designed to deliver broad clinical utility across multiple therapeutic areas. Our proprietary pipeline includes potentially first- or best-in-class programs for which we own global commercial rights. Arena is headquartered in San Diego, CA, with operations in Boston, MA, and Zug, Switzerland.

Corcept Therapeutics

Corcept Therapeutics Incorporated, a pharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of metabolic, oncologic, and psychiatric disorders in the United States. The company focuses on disorders that are associated with a steroid hormone called cortisol. It offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. The company is also developing Korlym’s active ingredient, which is in a Phase 1/2 trial in combination with the chemotherapy drug eribulin (Halaven) to treat patients with GR-positive triple-negative breast cancer, a form of cancer with a particularly poor prognosis; and CORT 125134, a proprietary, selective GR antagonist that is in a Phase 1 clinical study to assess its safety, tolerability, and pharmacokinetics in healthy human volunteers. In addition, it discovers and develops three series of novel selective GR-II antagonists. The company has research and development agreements with Argenta Discovery Limited and Sygnature Discovery Limited. Corcept Therapeutics Incorporated was founded in 1998 and is headquartered in Menlo Park, California.